Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | POLA1 | P09884 | 2/20 | 0.45 |
| ▸ | POLG | P54098 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.43 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.38 |
| ▸ | HPRT1 | P00492 | 4/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734845 | 0.88 | POLB (0.52) | POLBPOLA1POLGFGFR1SLC22A6 | |
| SCHEMBL23394748 | 0.86 | POLB (0.49) | POLBPOLA1POLGFGFR1SLC22A6 | |
| SCHEMBL2734838 | 0.85 | FGFR1 (0.58) | POLBPOLA1POLGFGFR1SLC22A6 | |
| SCHEMBL2734843 | 0.84 | POLB (0.52) | POLBPOLA1POLGFGFR1SLC22A6 | |
| SCHEMBL2734580 | 0.82 | POLB (0.47) | POLBPOLA1POLGFGFR1SLC22A6 | |
| SCHEMBL12339247 | 0.81 | SERPINA3 (0.48) | POLBPOLA1POLGFGFR1SLC22A6 | |
| SCHEMBL2734798 | 0.80 | POLB (0.76) | POLBPOLA1POLGFGFR1SLC22A6 | |
| SCHEMBL19413098 | 0.79 | POLB (0.74) | POLBPOLA1POLGHPRT1 | |
| SCHEMBL18755568 | 0.79 | FGFR1 (0.71) | POLA1POLGFGFR1SLC22A6ABCB11 | |
| SCHEMBL3328244 | 0.76 | FGFR1 (0.57) | POLBPOLA1POLGFGFR1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268802-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2204374-B1 | Nucleoside phosphonates and analogs thereof for the treatment of HPV-infections | GILEAD SCIENCES INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8088754-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2204374-A1 | Nucleoside phosphonates and analogs thereof for the treatment of HPV-infections | GILEAD SCIENCES, INC. (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7553825-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2007002912-A2 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002808-A1 | ANTI-NONMELANOMA CARCINOMA COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | POLB 82/4885POLA1 350/4885POLG 524/4885 |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | POLB 82/4885POLA1 350/4885POLG 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.